Gastrointestinal stromal tumour (GIST) - sunitinib malate
The Pharmaceutical Benefits Scheme subsidises sunitinib malate for patients with a metastatic or unresectable malignant gastrointestinal stromal tumour (GIST).
For adult patients with a metastatic or unresectable malignant gastrointestinal stromal tumour, treatment with sunitinib malate (Sutent®) can be subsidised through the PBS under section 85 of the National Health Act 1953.
Restrictions for prescribing sunitinib malate are outlined in the Schedule of Pharmaceutical Benefits on the PBS website.
Schedule item details
Dose - Sunitinib malate is available in capsule form:
- 12.5 mg capsules in a pack size of 28
- 25 mg capsules in a pack size of 28
- 37.5 mg capsule in a pack size of 28
- 50 mg capsules in a pack size of 28
- have a World Health Organisation performance status of 2 or less and have failed imatinib mesylate treatment due to resistance or intolerance, and
- meet the relevant criteria as indicated in the restrictions and be eligible for the PBS
Sunitinib malate is not PBS-subsidised for the treatment of patients with resectable malignant gastrointestinal stromal tumour.
Lodging an application
Initial application requests must be made in writing. Send all written applications to the Complex drugs address on the contact us page.
For a patient starting initial PBS-subsidised sunitinib malate treatment for gastrointestinal stromal tumour following failure of imatinib mesylate treatment due to resistance or intolerance, you must:
For more information contact us on the Complex Drug Enquiry line.